Merz North America Announces the Appointment of John Donofrio as Chief Financial Officer and Head of North American Business Development

Merz North America Announces the Appointment of John Donofrio as Chief Financial Officer and Head of North American Business Development

GREENSBORO, N.C.--(BUSINESS WIRE)--Merz North America (U.S. affiliate of Merz Pharma Group) today announced the appointment of John Donofrio as Chief Financial Officer and Head of Business Development – North America, effective immediately. In this role, Donofrio will be primarily accountable for financial performance, cost management and strategic business planning and analysis for the Finance organization in North America. Donofrio will join Merz's North American Leadership Team and will report directly to Bill Humphries, president and CEO of Merz North America, Inc.

"John has an impressive track record of building and leading teams across all finance disciplines. His past experiences have shown his ability to maximize synergies in the Finance organizations that he has managed, and he brings nearly two decades of experience in strategic financial management and corporate development within the specialty healthcare industry. His leadership will be essential during this period of tremendous growth for Merz North America, and we are extremely pleased that he has agreed to assume the responsibilities of Chief Financial Officer and Head of North American Business Development," said Bill Humphries, president & CEO of Merz North America, Inc.

Prior to joining Merz, Donofrio served as Vice President, Stiefel Global Finance for Stiefel, a GSK company. In that role, Donofrio was responsible for the financial strategy, management reporting, oversight and control framework for the global dermatology business unit, providing business partnering support for the U.S. dermatology business and global dermatology R&D team. Prior to this role, Donofrio was an integral member of the Stiefel Integration Core Team leading global integration activities within the finance organization.

Donofrio has more than 19 years of experience in a broad range of areas, including consolidated financial reporting, international accounting and internal controls, financial systems development and implementation, cost accounting, inventory management, budget and forecast planning, integration of mergers and acquisitions and business development.

Donofrio holds a degree in Accounting from North Carolina State University in Raleigh, NC. He will be based in Merz's North American headquarters in Greensboro, North Carolina.

About Merz North America

Merz North America is a specialty healthcare company that develops and commercializes innovative treatment solutions in medical and aesthetic dermatology, and neurology in the U.S. and Canada. Our ambition is to become a recognized leader in the treatment of movement disorders, and in aesthetics and dermatology. Our future is promising, and we are committed to advancing new therapeutic options and improving patients' lives. For more than 100 years, the development of Merz products has been based on our commitment to providing innovative medical approaches that earn trust of patients, physicians and partners worldwide. Globally, the companies of Merz Pharma Group are focused on medications for treating neurological and psychiatric illnesses, and they have assumed a leading role in the field of Alzheimer's disease research. Founded in 1908, Merz Pharma Group is a privately owned company headquartered in Frankfurt, Germany.

For more information about Merz or the Company's products, please visit www.merzusa.com.

Contacts

Merz North America
Mariana Smith, 336-217-2636
Cell: 615-631-6795
Corporate Communications
[email protected]

Suggested Articles

Journey Colab launches with $3 million from Apollo Projects to develop a pipeline of psychedelic compounds through a new development model.

Forma's lead asset, an IDH1 inhibitor, cleared cancer in one-third of patients with relapsed or refractory acute myeloid leukemia.

A type of white blood cell known as a granulocyte secretes growth factors that help axons of the central nervous system regenerate, researchers found.